MTOR and type 2 diabetes mellitus: In this sense, metformin (Metf), used in type 2 diabetes mellitus, has become a promising drug in oncology, acting, particularly through inhibition of the AMP-activated protein kinase (AMPK)/mTOR pathway [20,21].